ADMA Biologics, Inc. ADMA
Set alert
At close · Oct 30
After hours · Oct 30, 6:21 PM ET
- YTD
- -37.45%
- 1 year
- -25.28%
- Open
- 11.85
- Prev close
- 11.75
- Mkt cap
- 2.56B
- Vol
- 2.46M
- Avg vol
- 2.68M
- EPS
- 0.70
- P/E
- 16.30
- Div yield
- 0.00%
More statistics
- Low
- 11.37
- High
- 11.90
- Forward P/E
- 12.07
- Beta
- 0.69
- Short ratio
- 5.82
- Inst. own
- 92.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 9.97
- 200-d avg
- 10.99
- 1y target
- 17.00
5D chart
Signals (83)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:15 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:00 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:25 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:15 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:15 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 2:05 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:55 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:45 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:05 AM | 1 day ago |
| SMA: Bearish | Oct 30, 10:00 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:55 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:50 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:45 AM | 1 day ago |
| RSI: Overbought | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:05 PM | 2 days ago |
| RSI: Overbought | Oct 29, 3:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| RSI: Overbought | Oct 29, 11:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 2 days ago |
| RSI: Overbought | Oct 28, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 3 days ago |
| RSI: Overbought | Oct 27, 3:50 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:10 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:45 AM | 5 days ago |
News
1 day ago zacks.com
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.
2 days ago zacks.com
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
2 days ago zacks.com
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
4 days ago globenewswire.com
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026
RAMSEY, N.J. and BOCA RATON, Fla.
1 week ago zacks.com
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.
2 weeks ago globenewswire.com
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process
Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
2 weeks ago zacks.com
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
2 weeks ago defenseworld.net
ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis
Myriad Genetics (NASDAQ: MYGN - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
3 weeks ago zacks.com
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
3 weeks ago zacks.com
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
3 weeks ago defenseworld.net
ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from Analysts
Shares of ADMA Biologics Inc (NASDAQ: ADMA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat.com reports.…
1 month ago zacks.com
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
1 month ago zacks.com
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today
Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
1 month ago zacks.com
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
1 month ago zacks.com
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know
Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
1 month ago newsfilecorp.com
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board…
1 month ago zacks.com
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
1 month ago zacks.com
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
1 month ago zacks.com
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
1 month ago prnewswire.com
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA…
-
2 months ago benzinga.com
ADMA Biologics Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $559.495M Est
ADMA Biologics (NASDAQ:ADMA) affirms FY2026 sales outlook from $530.000 million-$560.000 million to $530.000 million-$560.000 million vs $559.495 million estimate.
-
2 months ago benzinga.com
ADMA Biologics Q2 Adj. EPS $0.16 Misses $0.17 Estimate, Sales $124.395M Miss $131.658M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.17 by 5.88 percent. This is a 14.29 percent increase over earnings of…
-
3 months ago benzinga.com
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.
5 months ago benzinga.com
Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech
Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.
-
5 months ago benzinga.com
Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18
Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
5 months ago benzinga.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
-
5 months ago benzinga.com
Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $20
Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $24 to $20.
5 months ago benzinga.com
Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
5 months ago benzinga.com
ADMA Biologics Sees FY2026 Sales $530.000M-$560.000M vs $632.367M Est
ADMA Biologics (NASDAQ:ADMA) sees FY2026 sales of $530.000 million-$560.000 million vs $632.367 million analyst estimate.
-
5 months ago benzinga.com
ADMA Biologics Q1 Adj. EPS $0.17 Misses $0.20 Estimate, Sales $114.493M Miss $141.800M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.20 by 15 percent. This is a 21.43 percent increase over earnings of $0.14…
-
6 months ago benzinga.com
ADMA Biologics Announces FDA Approval Of The Company's Supplemental Biologics License Application Submitted Under Section 351(a) Of The Public Health Service Act For ASCENIV
The FDA approval represents the final study report for the Pediatric assessment as required in the post marketing commitment.Additionally, the approval provides for a revision of ASCENIV's…
-
6 months ago benzinga.com
Canaccord Genuity Initiates Coverage On ADMA Biologics with Buy Rating, Announces Price Target of $21
Canaccord Genuity analyst Gary Nachman initiates coverage on ADMA Biologics (NASDAQ:ADMA) with a Buy rating and announces Price Target of $21.
6 months ago benzinga.com
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
7 months ago benzinga.com
Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday
U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend. Other gains: AGX 35.5%, MSC 24.5%, ADMA 13%, SGML 12.2%, KOD 10.5%, TBN 9.9%, METC 8.8%, U 8.3%,…
7 months ago benzinga.com
ADMA Biologics Slams Short Seller Claims, Highlights Strong Demand
ADMA Biologics stock rebounds premarket after a 30% drop tied to short seller claims, as the company defends demand and financial reporting.
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
7 months ago benzinga.com
ADMA Biologics Rebuts Short Seller Claims, Defends Product Demand
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics,…
7 months ago benzinga.com
Why Are Shares Of ADMA Biologics Falling Today?
ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has…
7 months ago benzinga.com
This Qualcomm Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
Wall Street analysts changed outlook on top names. View all changes on analyst ratings page. See what analysts think about QCOM stock.
7 months ago benzinga.com
Short Seller Report Alleges ADMA Biologics Financial Misrepresentation
ADMA Biologics shares drop after Culper Research short report alleges financial misreporting; company pushes back.
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
ADMA Responds To Short-Seller Report, Reviewing Assertions For Accuracy
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics,…
-
8 months ago benzinga.com
ADMA Biologics Q4 Adj. EPS $0.21 Beats $0.18 Estimate, Sales $139.163M Miss $139.400M Estimate
ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.18 by 16.22 percent. This is a 53.57 percent increase over earnings of…
8 months ago benzinga.com
Earnings Breakdown: ADMA Biologics Q4
Earnings Breakdown: ADMA Biologics Q4
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
